ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ARWR on Nasdaq
Shares outstanding
135,488,140
Price per share
$66.39
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
110,887,595
Total reported value
$3,823,621,448
% of total 13F portfolios
0%
Share change
+5,228,637
Value change
+$261,887,307
Number of holders
298
Price from insider filings
$66.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% +8.6% $1,349,258,642 +$86,995,199 20,323,221 +6.9% BlackRock, Inc. 31 Dec 2025
VANGUARD GROUP INC 11% $203,067,942 15,525,072 The Vanguard Group 30 Jun 2025
Avoro Capital Advisors LLC 8.3% -13% $183,357,661 -$8,136,887 11,517,441 -4.2% Avoro Capital Advisors LLC 30 Jun 2025
STATE STREET CORP 4.6% -10% $83,333,412 -$8,216,764 6,371,056 -9% STATE STREET CORPORATION 30 Jun 2025

As of 30 Sep 2025, 298 institutional investors reported holding 110,887,595 shares of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR). This represents 82% of the company’s total 135,488,140 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 20,224,825 +4.1% 0.01% $697,554,214
VANGUARD GROUP INC 12% 16,035,870 +3.3% 0.01% $553,077,156
Avoro Capital Advisors LLC 8% 10,900,000 +2.8% 4.9% $375,941,000
STATE STREET CORP 4.7% 6,397,364 +0.41% 0.01% $220,645,084
FMR LLC 4.3% 5,759,830 +11% 0.01% $198,656,549
Slate Path Capital LP 3.7% 4,982,000 -4.8% 2.7% $171,829,180
GEODE CAPITAL MANAGEMENT, LLC 2.3% 3,131,042 +5.1% 0.01% $108,008,198
Siren, L.L.C. 2% 2,669,880 0% 3.6% $92,084,161
Driehaus Capital Management LLC 1.5% 2,099,398 0.52% $72,408,237
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.5% 2,081,689 +3143% 0.05% $71,797,454
GOLDMAN SACHS GROUP INC 1.3% 1,773,878 -16% 0.01% $61,181,052
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 1.3% 1,759,489 -34% 0.01% $60,684,776
MORGAN STANLEY 1.3% 1,702,674 -0.15% 0% $58,725,264
BAKER BROS. ADVISORS LP 1.2% 1,670,762 +78% 0.42% $57,624,581
MARSHALL WACE, LLP 1.1% 1,436,840 -33% 0.05% $49,556,613
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.99% 1,345,860 +15% 0.01% $46,418,711
NORTHERN TRUST CORP 0.97% 1,311,590 +3.1% 0.01% $45,236,740
Fisher Asset Management, LLC 0.78% 1,053,794 +133% 0.01% $36,345,353
Woodline Partners LP 0.74% 1,000,158 +34% 0.16% $34,495,449
DEERFIELD MANAGEMENT COMPANY, L.P. 0.73% 993,000 0.52% $34,248,570
JANUS HENDERSON GROUP PLC 0.72% 973,567 +1853% 0.02% $33,534,515
UBS Group AG 0.68% 918,183 -43% 0.01% $31,668,132
Western Financial Corp/CA 0.61% 820,239 0% 12% $28,290,043
Bank of New York Mellon Corp 0.6% 814,548 -0.43% 0.01% $28,093,746
Balyasny Asset Management L.P. 0.59% 792,966 0.06% $27,349,397

Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,423,720 $160,999,662 +$931,444 $66.39 36
2025 Q3 110,887,595 $3,823,621,448 +$261,887,307 $34.49 298
2025 Q2 105,716,035 $1,671,181,802 +$44,748,502 $15.80 279
2025 Q1 103,362,113 $1,318,228,542 +$23,656,511 $12.74 258
2024 Q4 99,671,230 $1,873,827,796 +$70,601,159 $18.80 267
2024 Q3 95,670,815 $1,853,291,674 -$144,256,200 $19.37 269
2024 Q2 97,803,702 $2,541,555,930 +$100,080,138 $25.99 272
2024 Q1 94,985,928 $2,715,182,088 +$481,497,804 $28.60 270
2023 Q4 396,880 $12,144,529 -$1,975,204 $30.60 4
2023 Q3 73,454,971 $1,973,732,097 +$40,074,008 $26.87 249
2023 Q2 70,612,086 $2,517,287,905 -$38,471,703 $35.66 265
2023 Q1 72,934,652 $1,850,823,663 -$22,309,121 $25.40 249
2022 Q4 73,154,369 $2,965,005,091 +$98,081,416 $40.56 272
2022 Q3 70,075,128 $2,313,984,410 -$35,779,521 $33.05 259
2022 Q2 69,253,848 $2,438,221,367 +$114,552,688 $35.21 259
2022 Q1 66,998,249 $3,080,784,237 +$25,582,525 $45.99 287
2021 Q4 67,730,638 $4,490,506,608 +$59,730,137 $66.30 294
2021 Q3 65,929,133 $4,116,101,243 -$72,941,965 $62.43 283
2021 Q2 66,354,699 $5,493,349,365 -$133,230,103 $82.82 304
2021 Q1 67,908,512 $4,506,265,806 -$34,011,415 $66.31 281
2020 Q4 65,632,325 $5,036,733,227 +$76,184,272 $76.73 297
2020 Q3 68,040,925 $2,930,649,814 -$16,101,859 $43.06 250
2020 Q2 68,551,696 $2,959,919,209 +$126,517,230 $43.19 236
2020 Q1 65,369,329 $1,879,519,404 -$60,910,742 $28.77 225
2019 Q4 64,818,416 $4,111,035,094 -$251,371,708 $63.43 283
2019 Q3 65,503,501 $1,844,703,120 -$64,703,263 $28.18 213
2019 Q2 68,225,753 $1,809,116,980 +$469,494,191 $26.50 206
2019 Q1 58,944,394 $1,081,619,759 +$7,999,090 $18.35 172
2018 Q4 58,308,126 $723,961,442 -$833,184 $12.42 155
2018 Q3 54,742,179 $1,049,407,077 +$86,860,724 $19.17 129
2018 Q2 51,701,349 $703,080,428 +$174,618,683 $13.60 112
2018 Q1 40,698,272 $293,416,084 +$131,324,812 $7.21 88
2017 Q4 23,356,127 $85,874,621 +$30,320,983 $3.68 73
2017 Q3 15,003,494 $64,925,247 +$4,077,592 $4.33 54
2017 Q2 15,394,435 $24,938,147 -$15,533,434 $1.62 49
2017 Q1 24,317,910 $44,988,840 +$7,657,660 $1.85 76
2016 Q4 25,280,328 $39,181,542 -$54,572,463 $1.55 75
2016 Q3 30,121,780 $221,390,091 +$70,557,145 $7.35 93
2016 Q2 20,597,873 $109,582,112 +$97,609,296 $5.32 84
2016 Q1 2,128,149 $10,255,000 +$10,255,048 $4.82 6
2015 Q4 500 $4,000 $0 $8.00 1
2015 Q3 500 $3,000 $0 $6.00 1
2015 Q2 500 $4,000 $0 $8.00 1
2015 Q1 500 $4,000 $0 $8.00 1
2014 Q4 500 $4,000 $0 $8.00 1